Clinical Trial Detail

NCT ID NCT03969420
Title Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Tolero Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

Alvocidib + Cytarabine

Alvocidib

Age Groups: adult senior

No variant requirements are available.